Investigational therapies for renal disease-induced anemia

References

• Sato Y, Yanagita M. Renal anemia: from incurable to curable. Am J Physiol Renal Physiol. 2013;305(9):F1239–1248.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013;40(5):302–309.
   PubMed Web of Science ®Google Scholar
• Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111(12):992–1000.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Biosimilar recombinant human erythropoietins (“epoetins”) and future erythropoiesis-stimulating treatments. Expert Opin Biol Ther. 2012;12(5):581–592.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22(6):868–876.
   PubMed Web of Science ®Google Scholar
• Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. 2011;317(9):1261–1269.
   PubMed Web of Science ®Google Scholar
• Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019–2032.
   PubMed Web of Science ®Google Scholar
• Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584–590.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:288.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Bárány P, Covic A, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28(6):1346–1359.
   PubMed Web of Science ®Google Scholar
• Gaweda AE, Ginzburg YZ, Chait Y, et al. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015;30(2):187–196.
   PubMed Web of Science ®Google Scholar
• Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3(6):1691–1701.
   PubMed Web of Science ®Google Scholar
• Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015;90(1):12–23.
   PubMed Web of Science ®Google Scholar
• Charytan DM, Pai AB, Chan CT, et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015;26(6):1238–1247.
   PubMed Web of Science ®Google Scholar
• Gurusamy KS, Nagendran M, Broadhurst JF, et al. Iron therapy in anaemic adults without chronic kidney disease. Cochrane Database Syst Rev. 2014;12:CD010640.
   Google Scholar
• Susantitaphong P, Alqahtani F, Jaber BL. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis. Am J Nephrol. 2014;39(2):130–141.
   PubMed Web of Science ®Google Scholar
• Slotki I, Cabantchik ZI. The labile side of iron supplementation in CKD. J Am Soc Nephrol. 2015;26(11):2612–2619.
   PubMed Web of Science ®Google Scholar
• Macdougall IC. New anemia therapies: translating novel strategies from bench to bedside. Am J Kidney Dis. 2012;59(3):444–451.
   PubMed Web of Science ®Google Scholar
• Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394–410.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221–230.
   PubMed Web of Science ®Google Scholar
• Bonomini M, Del Vecchio L, Sirolli V, et al. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2016 Jan;67(1):133–142.
   PubMed Web of Science ®Google Scholar
• Rainville N, Jachimowicz E, Wojchowski DM. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis. Expert Opin Ther Targets. 2016 Mar;20(3):287–301.
   PubMed Web of Science ®Google Scholar
• Lakhal S, Talbot NP, Crosby A, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood. 2009;113(7):1555–1563.
   PubMed Web of Science ®Google Scholar
• Goetze O, Schmitt J, Spliethoff K, et al. Adaptation of iron transport and metabolism to acute high-altitude hypoxia in mountaineers. Hepatology. 2013;58(6):2153–2162.
   PubMed Web of Science ®Google Scholar
• Mitchell CJ, Shawki A, Ganz T, et al. Functional properties of human ferroportin, a cellular iron exporter reactive also with cobalt and zinc. Am J Physiol Cell Physiol. 2014;306(5):C450–459.
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783–788.
   PubMed Web of Science ®Google Scholar
• Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011;80(3):240–244.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Nemeth E, et al. Erythroferrone contributes to recovery from anemia of inflammation. Blood. 2014;124(16):2569–2574.
   PubMed Web of Science ®Google Scholar
• Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46(7):678–684.
   PubMed Web of Science ®Google Scholar
• Kim A, Nemeth E. New insights into iron regulation and erythropoiesis. Curr Opin Hematol. 2015;22(3):199–205.
   PubMed Web of Science ®Google Scholar
• Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142(1):24–38.
   PubMed Web of Science ®Google Scholar
• Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399–408.
   PubMed Web of Science ®Google Scholar
• Piperno A, Galimberti S, Mariani R, et al. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: data from the HIGHCARE project. Blood. 2011;117(10):2953–2959.
   PubMed Web of Science ®Google Scholar
• Talbot NP, Lakhal S, Smith TG, et al. Regulation of hepcidin expression at high altitude. Blood. 2012;119(3):857–860.
   PubMed Web of Science ®Google Scholar
• Ghosh MC, Zhang DL, Jeong SY, et al. Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2α. Cell Metab. 2013;17(2):271–281.
   PubMed Web of Science ®Google Scholar
• Wilkinson N, Pantopoulos K. IRP1 regulates erythropoiesis and systemic iron homeostasis by controlling HIF2α mRNA translation. Blood. 2013;122(9):1658–1668.
   PubMed Web of Science ®Google Scholar
• Steinbicker AU, Bartnikas TB, Lohmeyer LK, et al. Perturbation of hepcidin expression by BMP type I receptor deletion induces iron overload in mice. Blood. 2011;118(15):4224–4230.
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271–1276.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Wrighting DM, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet. 2006;38(5):531–539.
   PubMed Web of Science ®Google Scholar
• Andriopoulos B Jr, Corradini E, Xia Y, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009;41(4):482–487.
   PubMed Web of Science ®Google Scholar
• Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204–3209.
   PubMed Web of Science ®Google Scholar
• Verga Falzacappa MV, Vujic Spasic M, Kessler R, et al. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353–358.
   PubMed Web of Science ®Google Scholar
• Du X, She E, Gelbart T, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008;320(5879):1088–1092.
   PubMed Web of Science ®Google Scholar
• Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest. 2013;123(6):2337–2343.
   PubMed Web of Science ®Google Scholar
• Sun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87(4):392–400.
   PubMed Web of Science ®Google Scholar
• Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009;4(8):1384–1387.
   PubMed Web of Science ®Google Scholar
• Laarakkers CM, Wiegerinck ET, Klaver S, et al. Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. PLoS One. 2013;8(10):e75518.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Malyszko J, Hider RC, et al. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(9):1681–1689.
   PubMed Web of Science ®Google Scholar
• Kroot JJ, van Herwaarden AE, Tjalsma H, et al. Second round robin for plasma hepcidin methods: first steps toward harmonization. Am J Hematol. 2012;87(10):977–983.
   PubMed Web of Science ®Google Scholar
• Marino FE, Risbridger G, Gold E. The therapeutic potential of blocking the activin signalling pathway. Cytokine Growth Factor Rev. 2013;24(5):477–484.
   PubMed Web of Science ®Google Scholar
• Murata M, Eto Y, Shibai H, et al. Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin beta A chain. Proc Natl Acad Sci U S A. 1988;85(8):2434–2438.
   PubMed Web of Science ®Google Scholar
• Yu J, Shao LE, Lemas V, et al. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature. 1987;330(6150):765–767.
   PubMed Web of Science ®Google Scholar
• Shao L, Frigon NL Jr, Sehy DW, et al. Regulation of production of activin A in human marrow stromal cells and monocytes. Exp Hematol. 1992;20(10):1235–1242.
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Lu L, Cooper S, et al. Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin. Proc Natl Acad Sci U S A. 1988;85(23):9052–9056.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kosaka M, Mizuguchi T, et al. Effect of erythroid differentiation factor on maintenance of human hematopoietic cells in co-cultures with allogenic stromal cells. Biochem Biophys Res Commun. 1993;194(3):1103–1110.
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. Exp Cell Res. 2003;282(2):110–120.
   PubMed Web of Science ®Google Scholar
• Maguer-Satta V, Rimokh R. FLRG, member of the follistatin family, a new player in hematopoiesis. Mol Cell Endocrinol. 2004;225(1–2):109–118.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Kawano Y, Takaue Y, et al. Diminished erythropoietin-induced erythroid growth in patients with renal anemia is restored by recombinant human erythroid differentiation factor. Am J Hematol. 1994;47(3):178–182.
   PubMed Web of Science ®Google Scholar
• Carrancio S, Markovics J, Wong P, et al. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin. Br J Haematol. 2014;165(6):870–882.
   PubMed Web of Science ®Google Scholar
• Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721–1741.
   PubMed Web of Science ®Google Scholar
• Besson-Fournier C, Latour C, et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood. 2012;120(2):431–439.
   PubMed Web of Science ®Google Scholar
• Truksa J, Lee P, Beutler E. Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood. 2009;113(3):688–695.
   PubMed Web of Science ®Google Scholar
• Rochette L, Zeller M, Cottin Y, et al. Growth and differentiation factor 11 (GDF11): functions in the regulation of erythropoiesis and cardiac regeneration. Pharmacol Ther. 2015;156:26–33.
   PubMed Web of Science ®Google Scholar
• Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408–414.
   PubMed Web of Science ®Google Scholar
• Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol. 2010;17(3):184–190.
   PubMed Web of Science ®Google Scholar
• Smirnov IV, Vorobiev II, Belogurov AA, et al. Chemical polysialylation of recombinant human proteins. In: Glyco-engineering: methods and protocols; series. Methods Mol Biol. 2015;1321:389–404.
   PubMedGoogle Scholar
• Xenetic biosciences commences third cohort of Phase 2 trials on drug candidate erepoxen(R) for anemia. [cited 2014 Dec 14]. Available from: http://ir.xeneticbio.com/releasedetail.cfm? ReleaseID=931827.
   Google Scholar
• Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature. 1989;337(6207):525–531.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the efficacy and safety of GX-E2 in the anemic patients diagnosed with chronic kidney disease (CKD). [cited 2014 Dec 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02044653.
   Google Scholar
• Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med. 2013;368(4):320–332.
   PubMed Web of Science ®Google Scholar
• Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368(4):307–319.
   PubMed Web of Science ®Google Scholar
• Bennett CL, Jacob S, Hymes J, et al. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014;370(21):2055–2056.
   PubMed Web of Science ®Google Scholar
• Weinhandl ED, Gilbertson DT, Collins AJ, et al. Relative safety of peginesatide and epoetin alfa. Pharmacoepidemiol Drug Saf. 2014;23(10):1003–1011.
   PubMed Web of Science ®Google Scholar
• Bouman-Thio E, Franson K, Miller B, et al. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol. 2008;48(10):1197–1207.
   PubMed Web of Science ®Google Scholar
• Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol. 2009;20(6):692–699.
   PubMed Web of Science ®Google Scholar
• Bugelski PJ, Capocasale RJ, Makropoulos D, et al. CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol. 2008;134(1–2):171–180.
   PubMed Web of Science ®Google Scholar
• Sathyanarayana P, Houde E, Marshall D, et al. CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood. 2009;113(20):4955–4962.
   PubMed Web of Science ®Google Scholar
• Makropoulos DA, Achuthanandam R, Avery J, et al. CNTO 530 increases expression of HbA and HbF in murine models of β-thalassemia and sickle cell anemia. Curr Pharm Biotechnol. 2013;14(2):242–248.
   PubMed Web of Science ®Google Scholar
• Scully MS, Ort TA, James IE, et al. A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Exp Diabetes Res. 2011;2011:910159.
   PubMedGoogle Scholar
• Gong XL, Zhang XD, Li J, et al. Subchronic safety evaluation of EPO-018B, a pegylated peptidic erythropoiesis stimulating agent, after 5-week subcutaneous injection in cynomolgus monkeys and Sprague-Dawley rats. Food Chem Toxicol. 2013;60:252–262.
   PubMed Web of Science ®Google Scholar
• Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol. 2006;34(10):1303–1311.
   PubMed Web of Science ®Google Scholar
• Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release. 2001;72(1–3):217–224.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol. 2007;435:179–197.
   PubMed Web of Science ®Google Scholar
• Lippin Y, Dranitzki-Elhalel M, Brill-Almon E, et al. Human erythropoietin gene therapy for patients with chronic renal failure. Blood. 2005;106(7):2280–2286.
   PubMed Web of Science ®Google Scholar
• Hodson EM, Craig JC. Oral iron for patients receiving dialysis: what is the evidence? Semin Dial. 2014;27(1):8–10.
   PubMed Web of Science ®Google Scholar
• Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126(17):1981–1989.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88(4):905–914.
   PubMed Web of Science ®Google Scholar
• Maynor L, Brophy DF. Risk of infection with intravenous iron therapy. Ann Pharmacother. 2007;41:1476–1480.
   PubMed Web of Science ®Google Scholar
• Daugirdas JT, Blake PG, Ing TS, editors. Handbook of dialysis. Vol. 236. Philadelphia (PA): Lippincott Williams & Wilkins; 2007.
   Google Scholar
• Gupta A, Amin NB, Besarab A, et al. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int. 1999;55(5):1891–1898.
   PubMed Web of Science ®Google Scholar
• Gupta A, Lin V, Guss C, et al. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 2015;88(5):1187–1194.
   PubMed Web of Science ®Google Scholar
• Fishbane SN, Singh AK, Cournoyer SH, et al. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015;30(12):2019–2026.
   PubMed Web of Science ®Google Scholar
• Umanath K, Jalal DI, Greco BA, et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J Am Soc Nephrol. 2015;26(10):2578–2587.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Hasuike Y, Nanami M, et al. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited. Nephrol Dial Transplant doi:10.1093/ndt/gfv268. [Epub ahead of print].
   Google Scholar
• Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel). 2014;7(10):990–998.
   PubMedGoogle Scholar
• Van Buren PN, Lewis JB, Dwyer JP, et al. Collaborative study group. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis. 2015;66(3):479–488.
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Hider RC, Bloor JR, et al. Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test. J Clin Pharm Ther. 1991;16(2):117–122.
   PubMed Web of Science ®Google Scholar
• Reffit DM, Burden T, Seed PT, et al. Assessment of iron absorption from ferric trimaltol. Ann Clin Biochem. 2000;37(4):457–466. (2000-01-01).
   PubMed Web of Science ®Google Scholar
• Barrand MA, Callingham BA, Dobbin P, et al. Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat. Br J Pharmacol. 1991 Mar;102(3):723–729.
   PubMed Web of Science ®Google Scholar
• Stallmach A, Büning C. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859–2867.
   PubMed Web of Science ®Google Scholar
• Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21(3):579–588.
   PubMed Web of Science ®Google Scholar
• Dull RB, Davis E. Heme iron polypeptide for the management of anaemia of chronic kidney disease. J Clin Pharm Ther. 2015;40(4):386–390.
   PubMed Web of Science ®Google Scholar
• Minamishima YA, Kaelin WG Jr. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010;329(5990):407.
   PubMed Web of Science ®Google Scholar
• Barrett TD, Palomino HL, Brondstetter TI, et al. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015;172(16):4078–4088.
   PubMed Web of Science ®Google Scholar
• Soni H. Prolyl hydroxylase domain-2 (PHD2) inhibition may be a better therapeutic strategy in renal anemia. Med Hypotheses. 2014;82(5):547–550.
   PubMed Web of Science ®Google Scholar
• Rabinowitz MH. Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses. J Med Chem. 2013;56(23):9369–9402.
   PubMed Web of Science ®Google Scholar
• Kharbanda KK, Todero SL, King AL, et al. Betaine treatment attenuates chronic ethanol-induced hepatic steatosis and alterations to the mitochondrial respiratory chain proteome. Int J Hepatol. 2012;2012:459278.
   PubMedGoogle Scholar
• Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010;95(3):505–508.
   PubMed Web of Science ®Google Scholar
• Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014;25(3):564–572.
   PubMed Web of Science ®Google Scholar
• Corradini E, Schmidt PJ, Meynard D, et al. BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. Gastroenterology. 2010;139(5):1721–1729.
   PubMed Web of Science ®Google Scholar
• Babitt JL, Huang FW, Xia Y, et al. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933–1939.
   PubMed Web of Science ®Google Scholar
• Theurl I, Schroll A, Sonnweber T, et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood. 2011;118(18):4977–4984.
   PubMed Web of Science ®Google Scholar
• Willemetz A, Lenoir A, Deschemin JC, et al. Matriptase-2 is essential for hepcidin repression during fetal life and postnatal development in mice to maintain iron homeostasis. Blood. 2014;124(3):441–444.
   PubMed Web of Science ®Google Scholar
• Yu PB, Deng DY, Lai CS, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14(12):1363–1369.
   PubMed Web of Science ®Google Scholar
• Sun CC, Vaja V, Chen S, et al. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant. 2013;28(7):1733–1743.
   PubMed Web of Science ®Google Scholar
• Kajimoto H, Kai H, Aoki H, et al. BMP type I receptor inhibition attenuates endothelial dysfunction in mice with chronic kidney disease. Kidney Int. 2015;87(1):128–136.
   PubMed Web of Science ®Google Scholar
• Zhou L, McMahon C, Bhagat T, et al. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011;71(3):955–963.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol. 2010;28(23):3701–3708.
   PubMed Web of Science ®Google Scholar
• Song SN, Tomosugi N, Kawabata H, et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627–3634.
   PubMed Web of Science ®Google Scholar
• Fatih N, Camberlein E, Island ML, et al. Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form. J Mol Med (Berl). 2010;88(5):477–486.
   PubMed Web of Science ®Google Scholar
• Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115(17):3616–3624.
   PubMed Web of Science ®Google Scholar
• PRS-080. [ cited 2014 Dec 14]. Available from: http://www.pieris.com/pipeline/proprietary-programs/prs-080.
   Google Scholar
• NOX-H94. [ cited 2014 Dec 14]. Available from: http://www.noxxon.com/index.php?option=com_content&view=article&id=22&Itemid=479.
   Google Scholar
• Fung E, Sugianto P, Hsu J, et al. High-throughput screening of small molecules identifies hepcidin antagonists. Mol Pharmacol. 2013;83(3):681–690.
   PubMed Web of Science ®Google Scholar
• Witcher DR, Leung D, Hill KA, et al. LY2928057, An antibody targeting ferroportin, is a potent inhibitor of hepcidin activity and increases iron mobilization in normal cynomolgus monkeys. 55th ASH Annual Meeting and Exposition; 2013 Dec 7–10; New Orleans, LA.
   Google Scholar
• Li S, Nakayama T, Akinc A, et al. Development of LC-MS methods for quantitation of hepcidin and demonstration of siRNA-mediated hepcidin suppression in serum. J Pharmacol Toxicol Methods. 2015;71:110–119.
   PubMed Web of Science ®Google Scholar
• Souza TA, Chen X, Guo Y, et al. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol. 2008;22(12):2689–2702.
   PubMed Web of Science ®Google Scholar
• Ruckle J, Jacobs M, Kramer W, et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res. 2009;24(4):744–752.
   PubMed Web of Science ®Google Scholar
• Sherman ML, Borgstein NG, Mook L, et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of Sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol. 2013;53(11):1121–1130.
   PubMed Web of Science ®Google Scholar
• Dussiot M, Maciel TT, Fricot A, et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med. 2014;20(4):398–407.
   PubMed Web of Science ®Google Scholar
• Iancu-Rubin C, Mosoyan G, Wang J, et al. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap. Exp Hematol. 2013;41(2):155–166.
   PubMed Web of Science ®Google Scholar
• Raftopoulos H, Laadem A, Hesketh PJ, et al. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016;24(4):1517–1525.
   PubMed Web of Science ®Google Scholar
• Abdulkadyrov KM, Salogub GN, Khuazheva NK, et al. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014;165(6):814–823.
   PubMed Web of Science ®Google Scholar
• Fields SZ, Parshad S, Anne M, et al. Activin receptor antagonists for cancer-related anemia and bone disease. Expert Opin Investig Drugs. 2013;22(1):87–101.
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010;21(12):2151–2156.
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30(10):1665–1673.
   PubMed Web of Science ®Google Scholar
• Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27(4):1225–1233.
   PubMed Web of Science ®Google Scholar
• Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6–19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;pii: S0272–6386(16)00005-6. doi:10.1053/j.ajkd.2015.12.020. Epub ahead of print.
   Google Scholar
• Maxwell PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157–168.
   PubMed Web of Science ®Google Scholar
• Flamme I, Oehme F, Ellinghaus P, et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014;9(11):e111838.
   PubMed Web of Science ®Google Scholar
• Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27(4):1234–1244.
   PubMed Web of Science ®Google Scholar
• Brigandi RA, Johnson B, Oei C, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: A 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016;pii: S0272–6386(15)01495-X. doi:10.1053/j.ajkd.2015.11.021. Epub ahead of print.
   Google Scholar
• Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013;121(12):2311–2315.
   PubMed Web of Science ®Google Scholar
• Riecke K, Zollner S, Boyce M, et al. Single and repeated dose first-in-human study with the anti-hepcidin Spiegelmer NOX-H94 [abstract]. Am J Hematol. 2013;5(88):E4.
   Google Scholar
• van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 2014;124(17):2643–2646.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Rumjon A, Cinco J, et al. Pharmacokinetics and pharmacodynamics of lexaptepid, a novel anti-hepcidin molecule, in ESA-resistant haemodialysis patients 52nd ERA/EDTA congress London; 2015 May 28–31; London.
   Google Scholar
• Olson E, Demopoulos L, Haws TF, et al. Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vasc Med. 2014;19(6):473–482.
   PubMed Web of Science ®Google Scholar
• Boyce M, Warrington S, Cortezi B, et al. Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects. Br J Pharmacol. 2016;173:1580–1588. doi:10.1111/bph.13433. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Moslehi J, Minamishima YA, Shi J, et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010;122(10):1004–1016.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu J, Huang H. Recent agents targeting HIF-1α for cancer therapy. J Cell Biochem. 2013;114(3):498–509.
   PubMed Web of Science ®Google Scholar
• Lee K, Kim HM. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Arch Pharm Res. 2011;34(10):1583–1585.
   PubMed Web of Science ®Google Scholar
• Forristal CE, Levesque JP. Targeting the hypoxia-sensing pathway in clinical hematology. Stem Cells Transl Med. 2014;3(2):135–140.
   PubMed Web of Science ®Google Scholar